genedrive plc (LON:GDR – Get Free Report) dropped 10% during mid-day trading on Monday . The company traded as low as GBX 2.40 ($0.03) and last traded at GBX 2.47 ($0.03). Approximately 14,476,294 shares traded hands during mid-day trading, a decline of 1% from the average daily volume of 14,599,117 shares. The stock had previously closed at GBX 2.75 ($0.04).
genedrive Stock Down 10.0 %
The company has a current ratio of 1.63, a quick ratio of 5.52 and a debt-to-equity ratio of 8.57. The stock’s 50-day moving average price is GBX 2.38 and its 200-day moving average price is GBX 2.93. The stock has a market cap of £13.42 million, a price-to-earnings ratio of -68.63 and a beta of -0.04.
Insider Buying and Selling at genedrive
In other genedrive news, insider Ian David Gilham bought 1,000,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The shares were bought at an average price of GBX 3 ($0.04) per share, for a total transaction of £30,000 ($39,174.72). Insiders own 14.75% of the company’s stock.
genedrive Company Profile
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used forqualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
Read More
- Five stocks we like better than genedrive
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Top Stocks Investing in 5G Technology
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Breakout Stocks: What They Are and How to Identify Them
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for genedrive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for genedrive and related companies with MarketBeat.com's FREE daily email newsletter.